Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.04M Buy
+37,248
New +$1.05M 0.01% 1751
2026
Q1
Sell
-11,069
Closed -$438K 3830
2025
Q4
$438K Buy
11,069
+5,182
+88% +$190K 0.01% 1727
2025
Q3
$208K Sell
5,887
-14,139
-71% -$487K 0.01% 1819
2025
Q2
$656K Buy
20,026
+3,725
+23% +$121K 0.03% 924
2025
Q1
$526K Buy
+16,301
New +$605K 0.03% 997
2024
Q1
Sell
-7,796
Closed -$278K 1831
2023
Q4
$278K Buy
7,796
+513
+7% +$19.1K 0.06% 693
2023
Q3
$319K Buy
+7,283
New +$355K 0.05% 687
2023
Q2
Sell
-10,185
Closed -$422K 1408
2023
Q1
$422K Buy
+10,185
New +$423K 0.09% 399
2022
Q4
Sell
-5,986
Closed -$234K 1111
2022
Q3
$234K Buy
+5,986
New +$274K 0.06% 674

Other funds holding ATRC

XTX Topco's ATRC Position: Q2 2026 in Review

XTX Topco opened a new position in AtriCure (ATRC) in Q2 2026: 37,248 shares worth $1.04M. The stake represents 0.01% of the portfolio and ranks #1751 among its holdings. This is a return to the name: XTX Topco previously reported a position in ATRC as recently as Q4 2025.

XTX Topco first reported a position in ATRC in Q3 2022 and has held it in 9 quarters since. 252 funds tracked by Wall St. Rank hold ATRC as of Q2 2026.

  • XTX Topco held 37,248 shares of AtriCure worth $1.04M as of Q2 2026.
  • AtriCure was a new XTX Topco position in Q2 2026.
  • AtriCure made up 0.01% of XTX Topco's portfolio in Q2 2026, its #1751 holding.
  • XTX Topco first reported a position in AtriCure in Q3 2022 and has held it in 9 quarters since.
  • 252 funds tracked by Wall St. Rank held AtriCure as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.